lapatinib has been researched along with ficusin in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (ficusin) | Trials (ficusin) | Recent Studies (post-2010) (ficusin) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 1,049 | 37 | 331 |
| Protein | Taxonomy | lapatinib (IC50) | ficusin (IC50) |
|---|---|---|---|
| Nuclear factor NF-kappa-B p105 subunit | Homo sapiens (human) | 3 | |
| Acetylcholinesterase | Homo sapiens (human) | 6.48 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beyer, WF; Gooden, D; Liu, L; Soderblom, EJ; Spector, NL; Toone, EJ; Walder, H; Xia, W; Zhao, S | 1 |
1 other study(ies) available for lapatinib and ficusin
| Article | Year |
|---|---|
Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Catalytic Domain; Cell Line, Tumor; Cell Nucleus; Cross-Linking Reagents; Drug Resistance, Neoplasm; Female; Ficusin; Humans; Lapatinib; Molecular Targeted Therapy; Protein Kinase Inhibitors; PUVA Therapy; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Ultraviolet Rays | 2014 |